Forbes January 30, 2024
Alzheimer’s drugs work by targeting amyloid plaques in the brain. Research studies of those drugs, known as clinical trials, take on a broader target: proof in the form of specific clinical endpoints for each study. Today’s Alzheimer’s trials endpoints are typically a piece of paper published in 1993 and originally developed in the early 80’s.
The Clinical Dementia Rating, or CDR, “is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care.”
Ratings are based on a clinician’s “semi-structured interview of the patient and a reliable informant or collateral source (e.g. family member).” Here’s the scoring...
Today's Sponsors
Today's Sponsor